RELATED CONTENT
NEWS
- Lupin seeds research accord with Medicis while settling Solodyn dispute
- Regeneron submits BLA for VEGF Trap-Eye in wet AMD, but investors unimpressed
- US Krystexxa launch in motion, as Savient touts gout drug for "an unmet medical need", but concedes ramp-up may be slow
- AMAG, Allos to merge – but will it really bring sales synergies for Feraheme, Folotyn?


